HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) FOR THE PROSTATE CANCER TREATMENT: 5-YEAR RESUTS


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

During 2007-2012 748 patients with prostate cancer (PCa) underwent ultrasound ablation (HIFU). Patients were divided into 3 groups according to the prevalence and risk of disease progression: low risk (localized prostate cancer, 465 (62%) of patients) stage T1-2N0M0, total Gleason score ≤6, the level of prostate-specific antigen (PSA) less than 20ng/ml), high risk (locally advanced prostate cancer, 251 (34%) of patients) - stage T2-3N0M0, total Gleason score ≤9, the PSA level from 20 to 60 ng/ml, the presence of local recurrence after radical prostatectomy (RPE) and external beam radiation (EBRT) - 32 (4%) patients. Median follow-up after HIFU-therapy was 36 (3-54) months. At 12 and 48 months after treatment in patients with a low risk of progression median PSA was 0.2 and 0.5 ng/ml, in the group with a high risk 0.8 and 1.2 ng/ml, in patients with local recurrence after RPE and EBRT - 0.5 and 1.7ng/ml respectively. Generally HIFU treatment was successful in 90.9% of patients. It is shown that HIFU is safe minimally invasive treatment for localizes and locally advanced prostate cancer. It can be successfully performed in patients with local recurrence after RPE and EBRT.

Texto integral

Acesso é fechado

Bibliografia

  1. Jemal A. et al. Gender Statistics. 2010. CA Cancer J. Clin. 2010.
  2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009;20(3):1—156.
  3. Prostate Cancer Treatment Guidelines, v.2.2010.
  4. Лопаткин Н.А., Сивков А.В., Аполихин О.И. и др. Рак предстательной железы. М.: НИИ урологии Минздрава РФ, 2002.
  5. Thuroff S., Chaussy C., Vallancien G. et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multricentric study. J. Endourol. 2003;17(8):673—677.
  6. Djavan B., Moul J.W., Zlotta A. et al. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur. Urol. 2003;43(1):12—27.
  7. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. C.A. Cancer J. Clin. 2002;52:154—179.
  8. Tannock I.F., Osoba D., Stockler M.R. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996;14:1756—1764.
  9. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004;351:1513—1520.
  10. Tannock I.F., de Wit R., Berry W.R. et al. on behalf of the tax 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004;351:1502—1512.
  11. Blana A., Murat F.J., Walter B. et al. First analisys of the long-term result with High-intensity focused ultrasound with localised prostate cancer. Eur. Urol. 2008;53:1194—1201.
  12. Uchida T., Shoji S., Nakano M. et al. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int. J. Urol. 2009;16(11):881—886.
  13. Gelet A., Chapelon J.Y., Bouvier R. et al. Transrectal high intensity focused ultrasound for the treatment of localised prostate cancer: factors influencing the outcome. Eur. Urol. 2001;40:124—129.
  14. Монаков Д.М., Шаплыгин Л.В. Абляция предстательной железы высокоинтенсивным фокусированным ультразвуком при первично-множественных злокачественных заболеваниях. Актуальные проблемы оказания специализированной медицинской помощи. ФГУ ГВКГ им. Н.Н. Бурденко. М., 2009:103—104.
  15. Шаплыгин Л.В., Соловов В.А., Воздвиженский М.О. и др. Высокоинтенсивная фокусированная ультразвуковая абляция в лечении гормонорезистентного рака предстательной железы. Сибирский онкологический журнал. 2012;2:121—125.
  16. Аляев Ю.Г., Амосов A.B., Григорян В.А. и др. Рак простаты и HIFU-терапия. Урология. 2007;6:32—38.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2013

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies